A Phase 2 interventional study of Pemetrexed in Osteosarcoma, sponsored by Eli Lilly and Company. Completed at 13 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-28.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Osteosarcoma with a site in France — 7 open to participants now, 13 under way, 2 of them phase 3. Osteosarcoma · France.
Among the 36 studies in Osteosarcoma with a site in France, this one is the 26th largest by enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2007, is one of 12 in phase 2, and was the 6th registered.
488 studies on the registry are indexed under Osteosarcoma; 123 are open to participants now.
Browse Osteosarcoma studies →7 of the 36 studies in Osteosarcoma with a site in France are open now. Recruiting first, the newest first:
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France, Denmark, Finland and 5 more countries
Ages 4+
Centre Antoine Lacassagne · Sites in France
Ages 18+
Institut Bergonié · Sites in France
Ages 18+
Centre Leon Berard · Sites in France
Ages 12+
Université de Reims Champagne-Ardenne · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 100 Osteosarcoma studies recruiting now, 41 (41%) set no upper age limit and 55 (55%) stop at 75 or younger; 75 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 19 · Phase 3 4
First in 1994; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 40 across 354 interventional studies indexed under Osteosarcoma.
Median enrollment 91 across the 30 interventional studies, 62 across the 5 observational. Of the 19 that completed or were terminated, 9 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 36 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 3 studies filed under Osteosarcoma — fewer than ten, so there is no comparison to draw.
2 of the studies in Osteosarcoma with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05182164Institut BergoniéCombination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas | 2026-12 |
| NCT03496402Institut CurieBiological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO) | 2027-04-19 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies in Osteosarcoma with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of your participation in this study is to help answer the following research questions, and not to provide you treatment for your condition.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received pemetrexed 500 milligrams per square meter (mg/m\^2) by intravenous (IV) infusion of 10 minutes on Day 1 of each 21-day cycle.
Drug: Pemetrexed
500 mg/m\^2, IV every 21 days until disease progression, unacceptable toxicity, participant or physician's decision.
Also known as: LY231514, Alimta
Percentage of Participants With Tumor Response
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR) = disappearance of all target lesions; Partial Response (PR) = at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) = at least a 20% increase in sum of longest diameter of target lesions; Stable Disease (SD) = small changes that do not meet above criteria. Tumor Response Rate(%) = sum of number of PR + CR observed/number of participants qualified for tumor response analysis \* 100.
Time frame: Baseline to 21 months
Time to Treatment Failure
When the protocol was written, time to treatment failure (TTTF) was included as a secondary endpoint. However, it was subsequently realized that due to the design of the study, participants are treated until disease progression or discontinuation from study treatment, not for a fixed number of cycles. Therefore, it was concluded that analysis of TTTF was inappropriate with the current study design and the analysis was not conducted, since it would be essentially the same as Progression-Free Survival.
Time frame: Baseline to 21 months
Correlation of Disease Outcome With Pharmacogenomic Analysis
It was planned to examine methylthioadenosine phosphorylase (MTAP) gene deletion, folate receptor alpha (FRα) and folylpoly-gamma-glutamate synthetase (FPGS) expression, and to correlate the results with the clinical data to determine the association between these factors and clinical outcome to treatment. However, due to the small number of participants with partial response (n=1), the planned statistical analyses that would correlate responders/non responders with pharmacogenomics data are no longer valid and the analyses were not conducted.
Time frame: Baseline to 21 months
Number of Participants With Adverse Events (Pharmacology Toxicity)
Pharmacology toxicity was defined as serious and non-serious adverse events. Summaries of these adverse events are located in the Reported Adverse Event Section.
Time frame: Baseline to 21 months
Duration of Response
The duration of a complete response (CR) or partial response (PR) was defined as the time from the first objective status assessment of CR or PR to the first date of progression or death as a result of any cause: CR was achieved if all tumor lesions disappeared; PR was achieved if there was \>=30% decrease in sum of the longest diameter (LD) of target lesions (reference: baseline sum LDs) or complete disappearance of target lesions with persistence (but not worsening) of \>=1 nontarget lesions and no appearance of new lesions.
Time frame: Baseline to 31 months
Progression-Free Survival (PFS)
PFS was from date of study enrollment to first date of objectively determined progressive disease (PD) or death from any cause. For participants who did not die as of data cut-off date and who did not have objective PD, PFS was censored at date of last objective progression-free disease assessment. For participants who received subsequent systemic anticancer therapy (after discontinuation from study drug) before objectively determined disease progression or death, PFS was censored at date of last objective progression-free disease assessment, before post-discontinuation chemotherapy.
Time frame: Baseline to 10.4 months
Overall Survival (OS) Time
OS was the duration from enrollment to death. For participants who lived, OS was censored at the last contact.
Time frame: Baseline to 27.6 months
| Milestone | Pemetrexed |
|---|---|
| Started | 32 |
| Completed | 0 |
| Not completed | 32 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Physician decision | 2 |
| Withdrew: Progressive disease | 22 |
| Withdrew: Death due to study disease | 4 |
| Withdrew: Death due to adverse event | 2 |
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR) = disappearance of all target lesions; Partial Response (PR) = at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) = at least a 20% increase in sum of longest diameter of target lesions; Stable Disease (SD) = small changes that do not meet above criteria. Tumor Response Rate(%) = sum of number of PR + CR observed/number of participants qualified for tumor response analysis \* 100.
| percentage of participants | Pemetrexed |
|---|---|
| Response Rate | 3.1 (0.1 to 16.2) |
| Complete Response (CR) | 0 (0 to 0) |
| Partial Response (PR) | 3.1 (0.1 to 16.2) |
| Stable Disease (SD) | 15.6 (5.3 to 32.8) |
| Progressive Disease (PD) | 68.8 (50.0 to 83.9) |
| Unknown | 12.5 (3.5 to 29.0) |
When the protocol was written, time to treatment failure (TTTF) was included as a secondary endpoint. However, it was subsequently realized that due to the design of the study, participants are treated until disease progression or discontinuation from study treatment, not for a fixed number of cycles. Therefore, it was concluded that analysis of TTTF was inappropriate with the current study design and the analysis was not conducted, since it would be essentially the same as Progression-Free Survival.
No measurements were reported for this outcome.
It was planned to examine methylthioadenosine phosphorylase (MTAP) gene deletion, folate receptor alpha (FRα) and folylpoly-gamma-glutamate synthetase (FPGS) expression, and to correlate the results with the clinical data to determine the association between these factors and clinical outcome to treatment. However, due to the small number of participants with partial response (n=1), the planned statistical analyses that would correlate responders/non responders with pharmacogenomics data are no longer valid and the analyses were not conducted.
No measurements were reported for this outcome.
Pharmacology toxicity was defined as serious and non-serious adverse events. Summaries of these adverse events are located in the Reported Adverse Event Section.
| participants | Pemetrexed |
|---|---|
| Serious Adverse Events | 11 |
| All Other Nonserious Adverse Events | 26 |
The duration of a complete response (CR) or partial response (PR) was defined as the time from the first objective status assessment of CR or PR to the first date of progression or death as a result of any cause: CR was achieved if all tumor lesions disappeared; PR was achieved if there was \>=30% decrease in sum of the longest diameter (LD) of target lesions (reference: baseline sum LDs) or complete disappearance of target lesions with persistence (but not worsening) of \>=1 nontarget lesions and no appearance of new lesions.
| months | Pemetrexed |
|---|---|
| Duration of Response | 9.5 (4.0 to NA) |
PFS was from date of study enrollment to first date of objectively determined progressive disease (PD) or death from any cause. For participants who did not die as of data cut-off date and who did not have objective PD, PFS was censored at date of last objective progression-free disease assessment. For participants who received subsequent systemic anticancer therapy (after discontinuation from study drug) before objectively determined disease progression or death, PFS was censored at date of last objective progression-free disease assessment, before post-discontinuation chemotherapy.
| months | Pemetrexed |
|---|---|
| Progression-Free Survival (PFS) | 1.4 (1.4 to 1.7) |
OS was the duration from enrollment to death. For participants who lived, OS was censored at the last contact.
| months | Pemetrexed |
|---|---|
| Overall Survival (OS) Time | 5.5 (2.3 to 10.5) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed | — | 11/32 (34.4%) | 26/32 (81.3%) |
| Event | Pemetrexed |
|---|---|
| Pericardial effusionCardiac disorders | 2/32 |
| Febrile bone marrow aplasiaBlood and lymphatic system disorders | 1/32 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/32 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/32 |
| General physical health deteriorationGeneral disorders | 1/32 |
| PyrexiaGeneral disorders | 1/32 |
| Sudden deathGeneral disorders | 1/32 |
| Catheter related infectionInfections and infestations | 1/32 |
| SepsisInfections and infestations | 1/32 |
| Staphylococcal infectionInfections and infestations | 1/32 |
| Event | Pemetrexed |
|---|---|
| AstheniaGeneral disorders | 8/32 |
| Alanine aminotransferase increasedInvestigations | 7/32 |
| AnaemiaBlood and lymphatic system disorders | 6/32 |
| ConstipationGastrointestinal disorders | 5/32 |
| NauseaGastrointestinal disorders | 4/32 |
| FatigueGeneral disorders | 4/32 |
| Oedema peripheralGeneral disorders | 4/32 |
| Aspartate aminotransferase increasedInvestigations | 4/32 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/32 |
| ErythemaSkin and subcutaneous tissue disorders | 4/32 |
| Age Continuous(years) | Pemetrexed |
|---|---|
| Mean | 42.1 ± 16.28 |
| Sex: Female, Male(Participants) | Pemetrexed |
|---|---|
| Female | 12 |
| Male | 20 |
| Region of Enrollment(participants) | Pemetrexed |
|---|---|
| France | 13 |
| Spain | 3 |
| Germany | 6 |
| United Kingdom | 1 |
| Italy | 9 |
| Best Response of Last Prior Treatment Regimen for Osteosarcoma(participants) | Pemetrexed |
|---|---|
| Complete Response | 1 |
| Partial Response | 3 |
| Stable Disease | 10 |
| Progressive Disease | 15 |
| Not Applicable | 3 |
| Eastern Cooperative Oncology Group (ECOG) performance status(participants) | Pemetrexed |
|---|---|
| ECOG Performance Status 0 | 16 |
| ECOG Performance Status 1 | 14 |
| ECOG Performance Status 2 | 1 |
| ECOG Performance Status Not Available | 1 |
| Histopathological Diagnosis of Osteosarcoma at Study Entry(participants) | Pemetrexed |
|---|---|
| Number | 32 |
| Number of Target Lesions(participants) | Pemetrexed |
|---|---|
| 0 Target Lesions | 1 |
| 1 Target Lesion | 9 |
| 2 Target Lesions | 8 |
| 3 Target Lesions | 4 |
| 4 Target Lesions | 3 |
| 5 Target Lesions | 7 |
| Number of non target lesions(participants) | Pemetrexed |
|---|---|
| 0 Non Target Lesions | 10 |
| 1 Non Target Lesion | 15 |
| 2 Non Target Lesions | 5 |
| 3 Non Target Lesions | 1 |
| 5 Non Target Lesions | 1 |
2 further baseline measures are reported on the registry.
The record gives a start of Sep 2007, a primary completion of Jun 2009 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2010, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemetrexed